Effect of pretransplant depression on neutrophil recovery following hematopoietic stem cell transplantation

Figures & data

Table 1 Baseline demographics and relevant clinical data of the patients with and without depression

Variable		Patients with depression (N=35)	Patients without depression (N=38)	P-value
Age (years), mean ± SD		40.63±13.17	40.71±14.06	0.98
BMI (kg/m2), mean ± SD		25.02±3.74	26.33±3.41	0.123
Basal depression score, mean ± SD		11.74±2.55	3.29±2.06	<0.001
Sex, N (%)	Male	14 (40%)	19 (50%)	0.391
	Female	21 (60%)	19 (50%)
Marital status, N (%)	Single	6 (17.14%)	7 (18.42%)	0.887
	Married	29 (82.86%)	31 (81.58%)
Level of education, N (%)	Below high school	7 (20.0%)	12 (31.58%)	0.394
	High school	20 (57.14%)	16 (42.11%)
	Above high school	8 (22.86%)	10 (26.32%)
Type of disease, N (%)	AML	5 (14.29%)	6 (15.79%)	0.662
	ALL	8 (22.86%)	3 (7.89%)
	MM	6 (17.14%)	8 (21.05%)
	NHL	9 (25.71%)	12 (31.58%)
	HL	6 (17.14%)	8 (21.05%)
	Testicular germ cell tumor	1 (2.86%)	1 (2.63%)
Stage of disease, N (%)	PR	12 (34.29%)	14 (36.84%)	0.598
	GPR	5 (14.29%)	9 (23.68%)
	VGPR	4 (11.43%)	2 (5.26%)
	CR	14 (40.0%)	13 (34.21%)
Type of transplantation, N (%)	Allogenous	12 (34.29%)	9 (23.68%)	0.317
	Autologous	23 (65.71%)	29 (76.32%)
Conditioning regimen, N (%)	Myeloablative	30 (85.71%)	32 (84.21%)	0.858
	Non-myeloablative	5 (14.29%)	6 (15.79)
Stem cell source, N (%)	Peripheral blood	35 (100%)	38 (100%)	0.225

Notes: The bold data indicates the significance was 0.000 in the SPSS, which is usually shown as <0.001 in the articles.

Abbreviations: BMI, body mass index; AML, acute myelogenous leukemia; ALL, acute lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; PR, partial remission; GPR, good partial remission; VGPR, very good partial remission; CR, complete remission.

Table 2 Comparison of outcome after HSCT in patients with and without depression

Variable	Patients with depression (N=35)	Patients without depression (N=38)	P-value
Time to engraftment, mean ± SD	14.14±3.95	12.21±2.81	0.020
In-hospital duration, mean ± SD	29.66±8.82	27.34±6.29	0.198
Mortality during 1 year post-transplantation, N (%)	11 (31.43%)	5 (13.16%)	0.059
Mortality reason, N (%)
Relapse	6 (17.14%)	2 (5.26%)	0.590
Infection	4 (14.29%)	3 (7.89%)
GVHD	1 (2.85%)	0 (0%)
Complication during 1 year post-transplantation, N (%)	13 (37.14%)	9 (23.68%)	0.211
Readmission during 1 year post-transplantation, N (%)	18 (51.43%)	12 (31.58%)	0.085
Relapse during 1 year post-transplantation, N (%)	8 (22.86%)	5 (13.16%)	0.279

Notes: The bold data indicates the significance was 0.000 in the SPSS, which is usually shown as <0.001 in the articles.

Abbreviations: HSCT, hematopoietic stem cell transplantation; GVHD, graft-versus-host disease

Table 3 Comparison of inflammatory and anti-inflammatory markers between the two groups

Variable	Patients with depression (N=35)	Patients without depression (N=38)	P-value
IL–6, median (IQR)	243 (96–345)	86 (65–145)	<0.001
hs-CRP, median (IQR)	9 (3–22)	5 (3–12.25)	0.145
IL–10, median (IQR)	73 (45–118)	70 (47.25–132.25)	0.821
IL–6/IL–10 (IQR)	3.15 (1.14–5.44)	1.33 (0.79–2.01)	0.004

Notes: The bold data indicates the significance was 0.000 in the SPSS, which is usually shown as <0.001 in the articles.

Abbreviation: IQR, interquartile range.